[Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
In 61 out-patients with hyperlipoproteinemia type II the action of 50 mg Xantinol-nicotinate per kg body weight on lipids of plasma and lipoproteins was investigated in a three week trial. The results of six patients had been discharged: two patients failed to attend the follow-up examinations, in four patients a lipid lowering effect could not be demonstrated. 40 Type IIa patients and 15 Type IIb patients were examined. In this two groups cholesterol, phospholipids and triglycerides of plasma were significantly lowered. In Type IIa hyperlipoproteinemia mainly the LDL lipids and in Type IIb additionally the VLDL lipids decreased. In Type IIb patients the decrease of lipids were more rapid than in Type IIa patients. This effect is interpreted by the short half life of VLDL. Withdrawel of the drug resulted in an increase of the lipids to the mean values of the untreated patients within ten days.
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000097:blood; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood; D013806:Theophylline / Q000031:analogs & derivatives*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014971:Xanthinol Niacinate / Q000008:administration & dosage / Q000627:therapeutic use*
D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D014280:Triglycerides; D014971:Xanthinol Niacinate; D002784:Cholesterol; D013806:Theophylline
Therapie der Hyperlipoproteinämie Typ IIa und Typ IIb mit Xantinolnicotinat.